fulvestrant has been researched along with Lymphopenia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| André, F; Arnould, L; Bachelot, T; Berger, F; Bidard, FC; Bièche, I; Callens, C; Canon, JL; Chakiba, C; Clatot, F; D'Hondt, V; Dalenc, F; de la Motte Rouge, T; Delaloge, S; Derbel, O; Dubot, C; Ferrero, JM; Frenel, JS; Garnier-Tixidre, C; Grenier, J; Hardy-Bessard, AC; Ladoire, S; Lemonnier, J; Levy, C; Lortholary, A; Mouret-Reynier, MA; Pierga, JY; Pistilli, B; Plaza, JE; Pradines, A; Sabatier, R; Stefani, L; Teixeira, L; Vegas, H | 1 |
1 trial(s) available for fulvestrant and Lymphopenia
| Article | Year |
|---|---|
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Fulvestrant; Humans; Lymphopenia; Mutation; Neutropenia; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen | 2022 |